E135: IL17 and a GLP1?
From The Evidence Based Rheumatology Podcast by Michael Putman
April 30, 2026 · 11 min · Episode 136
About this episode
This episode discusses a study comparing the IL17 inhibitor ixekizumab with the GLP1 inhibitor tirzepatide.
Really interesting study this week comparing the IL17 inhibitor ixekizumab WITH the GLP1 inhibitor tirzepatide to ixekizumab alone. Raises some interesting questions about what worked here and whether or not it matters how it worked. Paper: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134 Newsletter: http://autoimmunedevreport.com/
People in this episode
Host: Michael Putman
Topics covered
- IL17 inhibitors
- GLP1 inhibitors
- rheumatology
- autoimmune diseases
- clinical studies
Keywords
- IL17
- GLP1
- ixekizumab
- tirzepatide
- rheumatology
- clinical study
- autoimmune
Mentioned in this episode
Organizations: autoimmunedevreport.com
Products: ixekizumab, tirzepatide
Books & works: https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.70134
More episodes of The Evidence Based Rheumatology Podcast
- E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
- E133: Obinutuzumab for SLE (ALLEGORY) · March 19, 2026 · 15 min
- E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
- E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
- E130: Telitacicept for SLE · December 22, 2025 · 13 min
- E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min
Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.